Cytomegalovirus and HLA-A, B, and DR locus interactions: Impact on renal transplant graft survival

American Journal of Kidney Diseases

Volumn 30, Issue 6, 1997, Pages 766-771

  Schnitzler, Mark A ^a   Woodward, Robert S ^b   Brennan, Daniel C ^b   Phelan, Donna L ^b   Spitznagel, Edward L ^b   Boxerman, Stuart B ^b   Dunagan, William C ^b   Bailey, Thomas C ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Cytomegalovirus; HLA typing; Kidney; Proportional hazards models

Indexed keywords

HLA A ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HLA SYSTEM; HUMAN; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; RISK FACTOR;

EID: 0030732498     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(97)90080-9     Document Type: Article

References (32)

1. Rubin RH: Infection in the renal and liver transplant patients, in Rubin RH, Young LS (eds): Clinical Approach to Infection in the Compromised Host (ed 2). New York, NY, Plenum Medical Books, 1988, pp 557-621
2. Gjertson DW: Multifactorial analysis of renal transplants reported to the United Network for Organ Sharing Registry: A 1994 update, in Terasaki PI, Cecka JM (eds): Clinical Transplants 1994. Los Angeles, CA, UCLA Tissue Typing Laboratory, 1995, pp 519-539
3. Fryd DS, Peterson PK, Ferguson RM, Simmons RL, Balfour HH Jr, Najarion JS: Cytomegalovirus as a risk factor in renal transplantation. Transplantation 3:436-439, 1980
4. Bailey T, Powderly W, Storch G, Dunkel J, Woodward R, Spitznagel E, Hanto D, Dunagan WC: Symptomatic cytomegalovirus infection in renal transplant recipients given either Minnesota anti-lymphoblast globulin (MALG) or OKT3 for rejection prophylaxis. Am J Kidney Dis 21:196-201, 1993
5. Glenn J: Cytomegalovirus infections following renal transplantation. Rev Infect Dis 3:1151-1178, 1981
6. Harfmann P, Dittmer R, Tenschert W, Cremaschi L, Meyer-Moldenhauer W-H, Arndt R, Klosterhalfen H: Association of HLA-A1, -A3, and -B15 with CMV disease in cytomegalovirus IgG-positive recipients of renal allografts. Transplant Proc 23:2660-2661, 1991
7. Salmela K, Höckerstedt K, Koskimies S, Lautenschlager I, Ahonen J: Is the susceptibility to recurrent CMV infection linked to certain HLA antigens in renal transplantation? Clin Transplant 4:216-219, 1990
8. Boland GJ, Hene RJ, Ververs C, DeHaan MAM, De-Gast GC: Factors influencing the occurrence of active cytomegalovirus (CMV) infections after organ transplantation. Clin Exp Immunol 94:306-312, 1994
9. Baldwin WM III, Claas FHJ, van Es A, Westedt WL, van Gemert G, Daha MR, van Es LA: Renal graft disfunction during infection with cytomegalovirus: Association with IgM lymphocytotoxins and HLA-DR3 and DR7. BMJ 287:1332-1334, 1983
10. Roenhorst HW, Tegzess AM, Beelen JM, Middeldorp JM, The TH: HLA-DRw6 as a risk factor for active cytomegalovirus but not for herpes simplex virus infection after renal allograft transplantation. BMJ 291:619-622, 1985
11. Kraat YJ, Christiaans MHL, Nieman FHM, Vanden Berg-Loonen PM, Van Hooff JP, Bruggeman CA: Increased frequency of CMV infection in HLA-DR7 matched renal allograft recipients. Lancet 341:494-495, 1993
12. Kraat YJ, Christiaans MHL, Nieman FHM, Vanden Berg-Loonen PM, Van Hooff JP, Bruggeman CA: Risk factors for cytomegalovirus infection and disease in renal transplant recipients: HLA-DR7 and triple therapy. Transpl Int 7:362-367, 1994
13. Haberal M, Demirag A, Turan M, Bilgin N, Büyükpamukçu N, Arslan G: Influence of HLA mismatching on the incidence of cytomegalovirus infection in living-related renal transplantations. Transplant Proc 27:2687-2690, 1995
14. Grundy JE, Ayles HM, McKeating JA, Butcher RG, Griffiths PD, Poulter LW: Enhancement of class I HLA antigen expression by cytomegalovirus: Role in amplification of virus infection. J Med Virol 25:483-495, 1988
15. Von Willebrand E, Pettersson E, Ahonen J, Hayn P: CMV infection, class II antigen expression, and human kidney allograft rejection. Transplantation 42:364-367, 1986
16. US Renal Data System: How good are the data? USRDS data validation study, in USRDS 1992 Annual Data Report. Bethesda, MD, The National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1992
17. Mytilineos J, Scherer A, Dunckley H, Trejaut J, Chapman J, Fischer G, Fae I, Middleton D, Savage D, Bignon J-D, Bensa J-C, Noreen H, Albert E, Opelz G: DNA HLA-DR typing results of 4000 kidney transplants. Transplantation 55:778-781, 1993
18. Opelz G, Mytilineos J, Scherer S, Dunckley H, Trejaut J, Chapman J, Fischer G, Fae I, Middleton D, Savage D: Analysis of HLA-DR matching in DNA-typed cadaver kidney transplants. Transplantation 55:782-785, 1993
19. Grint PCA, Ronalds CJ, Kangro HO, Campbell-Benzie A, Ward F, Hardiman AE, Heath RB: Screening tests for antibodies to cytomegalovirus: An evaluation of five commercial products. J Clin Pathol 38:1059-1064, 1985
20. Judge GG, Hill RC, Griffiths WE, Lutkepohl H, Tsoung-Chao L: Introduction to the Theory and Practice of Econometrics (ed 2). New York, NY, Wiley, 1988, pp 582-585
21. Fujimami RS, Nelson JA, Walker L, Oldstone BA: Sequence homology and immunologic cross-reactivity of human cytomegalovirus with HLA-DR β chain: A means for graft rejection and immunosuppression. J Virol 62:100-105, 1988
22. Hill AVS, Elvin J, Willis A, Aidoo M, Allsopp CEM, Gotch FM, Gao XM, Takiguchi M, Greenwood BM, Townsend ARM, McMichael AJ, Whittle HC: Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 360:434-439, 1992
23. McGuire W, Hill AVS, Allsopp CEM, Greenwood BM, Kwiatkowski D: Variation in the TNF-α promoter region associated with susceptibility to cerebral malaria. Nature 371:508-511, 1994
24. Thursz M, Kwiatkowski D, Allsopp CEM, Greenwood BM, Thomas HC, Hill AVS: Association of HLA class II allele with clearance of hepatitis B virus infection in The Gambia. N Engl J Med 332:1065-1069, 1995
25. Price P, Gibbons AE, Shellam GR: H-Z class I loci determine sensitivity to MCMV. Immunogenetics 32:20-26, 1990
26. Price P, Oliver SD, Gibbons AE, Teo MK, Shellam GR: Characterization of thymic induction induced by murine CMV infection. Immunol Cell Biol 71:155-165, 1990
27. Wykes MN, Shellam GR, McClusky J, Kast WM, Dallas PB, Price P: Murine CMV interacts with major histocompatibility complex class I molecules to establish cellular infection. J Virol 67:4182-4189, 1993
28. Scalzo AA, Lyons PA, Fitzgerald NA, Forbes CA, Yokoyama WM, Shellam GR: Genetic mapping of Cmv1 in the region of mouse chromosome 6 encoding the NK gene complex-associated loci Ly49 and musNKR-P1. Benomics 27:435-441, 1995
29. Farrell HE, Vally H, Lynch DM, Fleming P, Shellam GR, Scalzo AA, Davis-Poynter NJ: Inhibition of NKC by a CMV MHC class homologue in vivo. Nature 386:510-514, 1997
30. Reyburn HT, Mandelboim O, Valez-Goyez M, Davis DM, Paymany L, Shonizer JL: The class I MHC homologue of CMV inhibits attack by natural cells. Nature 386:514-517, 1997
31. Gane E, Saliba F, Baldecasas G, O'Grady J, Behrend M, Pescovitz MD, Pruett T, Hockerstedt K, Broelsch C, Mino-Fugaolas G, Houssin D, Davis C, Henry M, Erhard J, Kam I, King P, Robinson CA, Ganciclovir International Transplantation Study Group: Efficacy and safety of oral ganciclovir in the prevention of CMV disease in liver transplant recipients: Results of a multicenter multinational clinical trial. Am Soc Transplant Physicians Meeting, Dallas, TX, May 26-30, 1996, p 171 (abstr 346)
32. Singer GG, Storch GA, Burton KG, Lippmann BJ, Buller RS, Gaudreault-Keener M, Lowell JA, Shenoy S, Howard TK, Brennan DC: Prophylactic oral ganciclovir prevents cytomegalovirus disease in high-risk renal transplant recipients. J Am Soc Nephrol 7:000, 1996 (abstr 3469)